TJP2 and prostate cancer: Interestingly, reduced expression of claudin-5, ZO-1 and ZO-2 in the shAkt1 HLECs was rescued upon treatment with β-catenin inhibitors ICG001 and IWR-1, which resulted in the attenuation of DU145 prostate cancer cell invasion through shAkt1, compared to a shControl HLEC monolayer in vitro.